Hagop Kantarjian: NPM1-mutant myeloid neoplasms should be treated with AML-type treatment

Hagop Kantarjian shared on X:                .

“NPM1-mutant myeloid neoplasms should be treated with AML-type treatment irrespective of blast percentage. With intensive chemotherapy, maybe no need for SCT (Stem Cell Transplant).”

Source: Hagop Kantarjian/X

Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine. Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades.

His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib. Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.